Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Convertible Debt (2016 - 2018)

Viking Therapeutics (VKTX) has disclosed Convertible Debt for 5 consecutive years, with $1.5 million as the latest value for Q1 2018.

  • Quarterly Convertible Debt fell 59.6% to $1.5 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Mar 2018, down 59.6% year-over-year, with the annual reading at $1.5 million for FY2017, 0.0% changed from the prior year.
  • Convertible Debt hit $1.5 million in Q1 2018 for Viking Therapeutics, roughly flat from $1.5 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $3.7 million in Q1 2017 to a low of $1.3 million in Q4 2014.
  • Historically, Convertible Debt has averaged $1.8 million across 5 years, with a median of $1.5 million in 2016.
  • Biggest five-year swings in Convertible Debt: surged 119.57% in 2016 and later plummeted 59.6% in 2018.
  • Year by year, Convertible Debt stood at $1.3 million in 2014, then skyrocketed by 70.2% to $2.2 million in 2015, then crashed by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017, then changed by 0.0% to $1.5 million in 2018.
  • Business Quant data shows Convertible Debt for VKTX at $1.5 million in Q1 2018, $1.5 million in Q4 2017, and $1.5 million in Q3 2017.